2019 Marketing Pricing San Diego 
Xconomy
FEBRUARY 7, 2019
Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years. The amount raised surpassed expectations. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Xconomy
MARCH 1, 2019
biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch LA
DECEMBER 8, 2020
He did note that in the four markets where the company has gone live since launching its business in January 2019 — San Diego, Los Angeles, the Inland Empire , and Sacramento — has yielded an annualized revenue run rate of over $400 million in gross merchandise value (the total value of home sales transacted on its platform).
Xconomy
MAY 9, 2019
It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming. To date in 2019, 23 healthcare-related companies have gone public, the most of any sector.
Xconomy
JUNE 25, 2019
Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. percent compared to their offer price at IPO. On average, those companies’ shares are up 32.6
Xconomy
OCTOBER 28, 2016
THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases. The group filed shareholder resolutions with 11 companies and cited a Kaiser Family Foundation poll that cited Americans’ concerns over drug prices.
Xconomy
AUGUST 26, 2016
Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.
Expert insights. Personalized for you.
99 
Let's personalize your content